文献类型：期刊文献

英文题名：Light-Enabled [2σ+2π] Cycloadditions of Bicyclo[1.1.0]butanes and Alkenes by Ti-Salen Photocatalysis

作者：Xing, Jinping[1];Li, Dexia[1];Li, Tianxiang[1];Xu, Yang[1];Ren, Haosong[1];Zheng, Jun[1]

机构：[1]East China Univ Sci & Technol, Engn Res Ctr Pharmaceut Proc Chem, Sch Pharm, Minist Educ, Shanghai 200237, Peoples R China

年份：2026

卷号：4

期号：1

外文期刊名：CHEMISTRYEUROPE

收录：WOS:【ESCI(收录号:WOS:001816283800001)】；

基金：J.X., D.L., and T.L., contributed equally to this work. The authors are grateful for financial support from the Shanghai Scientific and Technological Innovation Projects (Grant No. 23ZR1417400), National Natural Science Foundation of China (Grant No. 22301075), East China University of Science and Technology for startup funding. The authors thank the Analysis and Testing Center of East China University of Science and Technology for help with NMR and HRMS analysis. The authors thank Prof. Long Chen at East China University of Science and Technology for help with cyclic voltammetry measurements.

语种：英文

外文关键词：benzenoid bioisostere; bridged bicyclic compounds; cycloaddition reaction; photoredox catalysis; titanium-salen complex

摘要：Bicyclo[2.1.1]hexanes (BCHs) have emerged as promising three-dimensional bioisosteres of benzenoids, garnering considerable interest from both synthetic and medicinal chemistry communities. In this study, we disclose a photoinduced intermolecular [2 sigma + 2 pi] cycloaddition reaction between bicyclo[1.1.0]butanes (BCBs) and alkenes, mediated by an unprecedented Ti(Salen) photocatalytic system. Under violet light irradiation (390 nm), the photoexcited Ti(Salen) complex promotes the cleavage of the central C-C bond in BCBs, enabling subsequent alkene insertion to afford polysubstituted BCHs with high efficiency. This Ti-catalyzed protocol features a broad substrate scope, good functional group compatibility, and mild reaction conditions. The operational simplicity and scalability of this transformation are further demonstrated by the concise synthesis of BCH-Lumacaftor-a conformationally restricted analog of the FDA-approved drug Lumacaftor-highlighting its potential for pharmaceutical applications.